Cabozantinib Description
Cabozantinib (CAS No.:1140909-48-3)(marketed under the tradename Cometriq, formerly known as XL184) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM. XL-184 also displays potent activity against Met, Ret, Kit, FLT1, FLT3, FLT4, Tie2, and AXL. XL184 at low concentration(0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion.
Functions of Cabozantinib Malate
Cabozantinib is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis.
Cabozantinib is approved for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.
Cabozantinib Malate Usage And Synthesis
Cabozantinib Malate Dosage: The recommended dosage is 140 mg daily (1 capsule 80 mg and 3 capsules 20 mg). Avoid food with the same service. Instruct patients to take medicine for 2 hours before taking medicine within 1 hour. Continue medication until disease progression or intolerable adverse reactions.
